Risk Factors for early CMV reactivation and Impact of early CMV reactivation on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide.

Authors:

Mariotti J, Legrand F, Furst S, Giordano L, Magri F, Richiardi L, Granata A, De Philippis C, Maisano V, Faraci D, Sarina B, Giaccone L, Harbi S, Mannina D, Valli V, Tordato F, Mineri R, Bramanti S, Santoro A, Bruno B, Devillier R, Blaise D, Castagna L.

Source:

Transplant Cell Ther 2022; 28: 169.e1-169.e9. doi: 10.1016/j.jtct.2021.12.014. Epub 2021 Dec 23. PMID: 34954296

This website only uses technical cookies and does not collect personal data or use profiling cookies. By continuing to browse, you accept the use of cookies.